Earlier this week, Merck entered into an agreement to acquire Tilos Therapeutics for up to $773 million. Tilos is a privately held biopharmaceutical firm developing therapeutics that target the latent transforming growth factor beta (TGF-β) complex.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,